Physician
Yibas, Markos
Yibas, Markos was paid $1.38M by Medicaid between Feb 2023 and Dec 2024, across 34 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 50% of everything it billed.
33Billing provider infoYIBAS, MARKOS
GREENBELT, MD 20770
GREENBELT, MD 20770
33aNPI1467490094assigned 06/04/2006
33bProvider typePediatrics Physician
28Total paid$1.38M
24GClaims21,200
24DCodes billed34
24AFirst – last monthFeb 2023 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Maryland
Rank by total paid#78 of 306
Median peer was paid$206K
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 8,634 | $540K | |
| 2024incomplete | 12,566 | $840K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 50% | 7,857 | 6,802 | $685K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 12% | 1,474 | 1,338 | $160K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 11% | 1,554 | 1,422 | $155K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.8% | 1,088 | 1,006 | $108K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.5% | 693 | 638 | $63K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.5% | 312 | 292 | $34K |
| 90662 | 1.9% | 534 | 527 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 859 | 830 | $18K |
| 90670 | 1.1% | 749 | 683 | $15K | |
| 90651 | 1.1% | 708 | 646 | $15K | |
| 90698 | <1% | 678 | 623 | $13K | |
| 90621 | <1% | 314 | 290 | $11K |
22 more codes
| 99051 | <1% | 998 | $9K | |
| 90734 | <1% | 428 | $9K | |
| 90633 | <1% | 462 | $9K | |
| 90619 | <1% | 199 | $9K | |
| 90715 | <1% | 396 | $8K | |
| 90744 | <1% | 353 | $7K | |
| 90680 | <1% | 226 | $4K | |
| 90710 | <1% | 194 | $4K | |
| 90696 | <1% | 195 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 226 | $4K |
| 90716 | <1% | 159 | $3K | |
| 90707 | <1% | 151 | $3K | |
| 90681 | <1% | 87 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 94 | $1K |
| 99381 | <1% | 13 | $714.30 | |
| 90671 | <1% | 21 | $569.04 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 27 | $225.52 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 45 | $69.84 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 36 | $23.28 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 30 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 15 | $0.00 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.